These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2029213)

  • 21. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
    Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
    J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum level of interleukin-10 in patients with systemic sclerosis.
    Kucharz EJ; Brzezinska-Wcislo L; Kotulska A; Gasiorowska-Kielkowska W; Gozdzik J
    Clin Rheumatol; 1997 Nov; 16(6):638-9. PubMed ID: 9456024
    [No Abstract]   [Full Text] [Related]  

  • 23. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
    Steen VD; Engel EE; Charley MR; Medsger TA
    J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis.
    Nakamura K; Asano Y; Taniguchi T; Minatsuki S; Inaba T; Maki H; Hatano M; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    J Dermatol; 2016 Aug; 43(8):912-8. PubMed ID: 26777734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.
    Sharief MK; Thompson EJ
    J Neurol Neurosurg Psychiatry; 1993 Feb; 56(2):169-74. PubMed ID: 8437006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased serum interleukin 23 in patients with systemic sclerosis.
    Komura K; Fujimoto M; Hasegawa M; Ogawa F; Hara T; Muroi E; Takehara K; Sato S
    J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble Fas levels in patients with systemic sclerosis.
    Bianchi T; Bardazzi F; Patrizi A
    Arch Dermatol Res; 2000 Oct; 292(10):522-3. PubMed ID: 11142775
    [No Abstract]   [Full Text] [Related]  

  • 28. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Internal organ lesions in acrosclerosis patients: interleukin-2 and soluble receptor for interleukin-2 plasma levels.
    Chibowska M; Krasowska D; Weglarz J
    J Eur Acad Dermatol Venereol; 2000 May; 14(3):234-6. PubMed ID: 11032081
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum prolidase activity in systemic sclerosis.
    Celik A; Birer MN; Kilinc M
    Clin Rheumatol; 2017 Aug; 36(8):1827-1832. PubMed ID: 28534076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.
    Tokano Y; Murashima A; Takasaki Y; Hashimoto H; Okumura K; Hirose S
    Ann Rheum Dis; 1989 Oct; 48(10):803-9. PubMed ID: 2818016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum-soluble interleukin-2 receptor concentrations in patients with breast cancer: a preliminary report.
    Sheen-Chen SM; Chen WJ; Eng HL; Chou FF
    Changgeng Yi Xue Za Zhi; 1998 Jun; 21(2):133-8. PubMed ID: 9729645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of mannose-binding lectin in systemic sclerosis: a possible contribution to the initiation of skin sclerosis in the diffuse cutaneous subtype.
    Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Eur J Dermatol; 2014; 24(1):123-5. PubMed ID: 24566202
    [No Abstract]   [Full Text] [Related]  

  • 36. Soluble interleukin-2 receptor and soluble CD8 molecules in cerebrospinal fluid and serum of patients with multiple sclerosis.
    Carrieri PB; Soscia E; Iacovitti B; Pellicano M; D'Antonio A; Provitera V; Perrella O
    Eur Cytokine Netw; 1992; 3(5):495-8. PubMed ID: 1477299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells.
    Mueller C; Knoflach P; Zielinski CC
    Gastroenterology; 1990 Mar; 98(3):639-46. PubMed ID: 2298368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis.
    Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Br J Dermatol; 2012 Sep; 167(3):542-7. PubMed ID: 22540233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.